pharmaphorum

APRIL 27, 2021

On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively. The post FDA looks at pulling speedy approvals for three cancer drugs appeared first on.

FDA 90

FDA Chemotherapy Documentation 90

pharmaphorum

OCTOBER 6, 2022

The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.

Generic Medicine 98

Generic Medicine Chemotherapy 98

pharmaphorum

AUGUST 4, 2022

The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had seen disease progression despite earlier treatment with an anti-hormonal therapy.

Chemotherapy 105

Chemotherapy Labelling FDA 105

European Pharmaceutical Review

OCTOBER 19, 2023

The development of novel radiotherapeutics ushered in a new era in targeted treatment 1 for cancer, with two separate radiotherapeutic approvals in Europe and the US, in 2018 and 2022. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy?

Chemotherapy 105

Chemotherapy Compounding Immunization FDA 105

pharmaphorum

JUNE 7, 2021

” J&J paid Argenx a hefty $300 million upfront to secure rights to cusatuzumab (also known as JNJ-4550) in December 2018, and also made a $200 million equity investment in the Belgian company as part of a deal that had a total value of $1.6

Chemotherapy 64

Chemotherapy Immunization 64

pharmaphorum

JANUARY 19, 2021

In 2018, Pfizer’s ALK and ROS1 inhibitor Xalkori (crizotinib) was cleared by NICE in England – via the Cancer Drugs Fund (CDF) – as well as in Scotland by the SMC as a first-line option for treating ROS1-positive advanced NSCLC in adults.

Chemotherapy 98

Chemotherapy Immunization 98

pharmaphorum

NOVEMBER 18, 2021

The company is also looking at applications including pain during childbirth or trauma, or tackling the discomfort caused by some treatments such as cancer chemotherapy. Lower back pain is one of the top causes of disability around the world, and according to a 2018 report in The Lancet accounts for 189 million lost working days and $62.4

FDA 98

FDA Chemotherapy 98

pharmaphorum

AUGUST 3, 2022

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC). billion in 2018. million) in sales for the product in the first six months of this year, a rise of 30% at constant exchange rates.

Chemotherapy 52

Chemotherapy FDA 52

pharmaphorum

DECEMBER 4, 2020

J&J’s Janssen unit is seeking approval of the drug in a specific patient group – those with exon 20 insertion mutations whose disease has progressed despite first-line chemotherapy. The median durations of response were 10 months and seven months, respectively.

FDA 93

FDA Chemotherapy 93

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy 52

Chemotherapy FDA Labelling Immunization 52

pharmaphorum

DECEMBER 21, 2020

Data from trials of the drug wowed ESMO in September – Trodelvy was shown to significantly extend overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared with standard chemotherapy in TNBC patients with brain metastases treated with at least two therapies. months, compared with 6.7

Chemotherapy 126

Chemotherapy Immunization FDA 126

pharmaphorum

FEBRUARY 24, 2021

The main object of the deal is Merck’s MEK 1/2 inhibitor pimasertib, a drug it originally licensed from Santhera Pharmaceuticals more than a decade ago, bringing the drug to phase 2 in melanoma and ovarian cancer and running trials in various other solid tumours and blood cancers before shelving it in 2018.

Chemotherapy 83

Chemotherapy Compounding FDA 83

IDStewardship

DECEMBER 26, 2022

As someone who enjoys the simplicity of Sesame Street and the complexity of Antimicrobial Chemotherapy, this one was near and dear to my heart as well as a long time coming. November 2018 – www.LearnAntibiotics.com created. EDITOR’S CHOICE: BEST ARTICLE OF 2022. This was the most fun article to work on this year.

Chemotherapy 130

Chemotherapy Hospitals 130

pharmaphorum

JANUARY 5, 2021

Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

pharmaphorum

MARCH 18, 2021

Keytruda (pembrolizumab) was being reimbursed on an interim basis for advanced or metastatic urothelial carcinoma, following platinum based chemotherapy, by the Cancer Drugs Fund (CDF) until survival data from a larger study emerged.

Chemotherapy 52

Chemotherapy Documentation 52

Hospital Pharmacy Europe

APRIL 12, 2024

Final draft guidance for the treatment , which has been available through the NHS Cancer Drugs Fund (CDF) since December 2018, recommends tisagenlecleucel for children and young adults up to and including 25 years of age who have B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

Chemotherapy 52

Chemotherapy Hospitals 52

pharmaphorum

FEBRUARY 17, 2021

At an interim analysis, Lynparza (olaparib) reduced recurrence of disease compared to placebo in women with BRCA-mutated, HER2-negative breast cancer after surgery and chemotherapy to remove the tumour.

Chemotherapy 59

Chemotherapy 59

Druggist

MARCH 11, 2021

Treatment, for example, chemotherapy and radiotherapy. Patients should avoid using glycerin and lemon juice, which dehydrate the mouth and cause exhaustion of salivary secretions (NICE, 2018). Almoudi MM, Hussein AS, Abu Hassan MI, Mohamad Zain N (2018). NICE (2018). List of common drugs that cause dry mouth. References.

Chemotherapy 97

Chemotherapy Packaging 97

Pharmaceutical Technology

MAY 12, 2023

The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. Eisai signed a licensing agreement with BlissBio in 2018 for the Chinese companies’ exclusive right to use eribulin as their ADC payload.

Chemotherapy 64

Chemotherapy Compounding 64

The Checkup by Singlecare

DECEMBER 14, 2023

You should also speak to your healthcare provider about any medication side effects and follow up if your symptoms persist or worsen after treatment.

Chemotherapy 105

Chemotherapy Dosage 105

Pharmaceutical Technology

SEPTEMBER 26, 2022

It provides a further valuable treatment option that can increase the time they remain in good health and delay the need for chemotherapy and its associated side effects. “As In addition to palbociclib, NICE has granted approval for 15 other therapies for breast cancer since 2018.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

APRIL 20, 2021

Zytiga is the older of the two drugs and was used in the active control arm of the ACIS study, which tested the combination of Erleada (apalutamide) and Zytiga (abiraterone) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Chemotherapy 52

Chemotherapy FDA 52

pharmaphorum

DECEMBER 2, 2020

Aside from Gazyvaro, CLL can be treated with older chemotherapy agents, or Roche/AbbVie’s Venclexta (venetoclax) in some instances, and the fast track tag showed the FDA considered the combination to be a promising new contender on the market.

FDA 52

FDA Chemotherapy 52

The Checkup by Singlecare

APRIL 14, 2024

Certain supplements, flea medications, and chemotherapy drugs may also cause adverse reactions. However, they also say some research has shown toxicity at lower doses, such as this 2018 study , which recommended caution with doses greater than 40 mg/kg/day. How much metronidazole can I give my dog?

Dosage 98

Dosage Adverse Reactions Chemotherapy Labelling 98

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology.

Chemotherapy 132

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 132

pharmaphorum

DECEMBER 6, 2022

Ezutromid was abandoned in 2018 on phase 2 data, with Summit turning its attention ridinilazole only for the drug to miss the mark in a phase 3 study reported earlier this year, leaving the company with early-stage antibiotic and oncology projects.

Chemotherapy 52

Chemotherapy Immunization 52

pharmaphorum

OCTOBER 13, 2020

The Geneva-based company has been operating under the radar since being formed to develop CRD1, a new oral formulation of the long-established drug chemotherapy cladribine which has been used intravenously as a treatment for leukaemia for years.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

NOVEMBER 11, 2021

months in patients treated with chemotherapy. China’s pharma market was worth $137 billion in 2018 and is predicted to reach $140 to $170 billion by 2023, according to data from IQVIA. months, compared with 6.7 Learn more. link] #TNBC pic.twitter.com/as7B9X7p5T. — Gilead Sciences (@GileadSciences) November 11, 2021.

Chemotherapy 52

Chemotherapy FDA 52

pharmaphorum

APRIL 23, 2021

While some argued that GSK overpaid for Tesaro in 2018, at least the deal is bringing badly needed new drugs to market for the under-pressure UK pharma and its highly-paid research chief Hal Barron.

FDA 52

FDA Chemotherapy Labelling 52

pharmaphorum

SEPTEMBER 29, 2020

China’s Junshi Biosciences has said it plans filings for a new cancer immunotherapy after its toripalimab outperformed standard chemotherapy in cancer of the upper throat in a phase 3 trial. Toripalimab was first approved in second line metastatic melanoma in China in December 2018 and launched in February last year.

Chemotherapy 40

Chemotherapy FDA 40

Hospital Pharmacy Europe

SEPTEMBER 5, 2022

In 2018 she moved to Saint Louis to take part in the CAR-T cell project. The unit has 16 beds and treats patients with chemotherapy and CAR-T cell therapy. It is a busy department, which, according to Dr di Blasi, in 2021, ‘ took care of ‘661 patients, which included 450 new patients.’.

Chemotherapy 52

Chemotherapy Hospitals Immunization 52

pharmaphorum

MAY 24, 2021

The study also included an arm that combined amivantamab with lazertinib, an experimental EGFR tyrosine kinase inhibitor (TKI) that J&J licensed from South Korea’s Yuhan in 2018, which showed a 100% ORR with the combination in previously-untreated EGFR-mutant NSCLC.

FDA 52

FDA Chemotherapy Immunization 52

The Checkup by Singlecare

MARCH 23, 2023

The United States Congress legalized CBD derived from hemp in 2018 when the Agricultural Improvement Act was signed into law, removing hemp from the Federal Controlled Substances Act. The main difference is their legal status: CBD is considered legal if it comes from hemp , according to the Agriculture Improvement Act in 2018.

Controlled Substances 52

Controlled Substances Medical Records Chemotherapy Compounding 52

Hospital Pharmacy Europe

AUGUST 29, 2024

These patients often reach the ceiling for toxicity in terms of chemotherapy and radiotherapy in the context of a bone marrow transplant. It’s a good way forward – much easier than delivering chemotherapy or transplant given the long-term side effects of these treatments. We’re investigating ways to do that and are collecting data.

Chemotherapy 52

Chemotherapy Immunization Patient Care Hospitals 52

The Thyroid Pharmacist

SEPTEMBER 20, 2024

One 2018 study found that among 80 people with IBS, 19 percent had undiagnosed thyroid dysfunction. [11] Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Published 2018 Nov 28.

Health and Personal Care Stores 84

Health and Personal Care Stores Chemotherapy Immunization Compounding 84

Pharmaceutical Technology

SEPTEMBER 23, 2022

The current standard of care for many cancers is cisplatin chemotherapy or platinum therapy. In 2018, the FDA had granted Pedmark a breakthrough orphan drug designation. More than double the volume of Fennec’s shares were traded on the day of the approval news in comparison to 19 September.

FDA 52

FDA Communication Chemotherapy Labelling 52

Roots Analysis

OCTOBER 4, 2023

One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy.

Chemotherapy 40

Chemotherapy Immunization FDA 40